Protein That Fuels Cancer Can Be Reprogrammed to Fight It, Scientists Find

Scientists at Cold Spring Harbor Laboratory (CSHL), led by Assistant Professor Semir Beyaz, published findings on October 14, 2026, detailing a new method to re-engineer the protein peroxisome proliferator-activated receptor delta (PPARD) to strengthen immune cell attacks against various cancers[1][2][4][5]. This discovery could offer new treatment strategies for aggressive cancers like colorectal cancer, which often resist conventional therapies[4][9][11].

What the records show

The research, published in Nature Immunology, centers on PPARD, a protein previously associated with fueling cancer growth[2][6]. Beyaz's team found that activating PPARD within immune cells dramatically alters the tumor microenvironment, shifting it towards an anti-cancer response[4][12]. This metabolic reprogramming allows immune cells to process fats more efficiently for energy, boosting their capacity to combat tumors[4][9]. Beyaz explained that "What cells eat affects who they are. When immune cells burn more fat, they become more fit for fighting cancer"[4][12].

The team's initial experiments involved mice with colorectal cancer[4][9]. They then tested PPARD-activated CAR T cells, a type of engineered immune cell, against human colorectal cancer models[3][4]. These models included organoids, miniature tumors grown from patient tissue samples, lab-grown human cancer cells, and human cancer cells implanted into mice[4][9][12]. In all these laboratory settings, the PPARD-activated CAR T cells demonstrated a significant ability to slow or stop tumor growth[4][12].

The approach showed promise against a range of cancers, including colorectal, breast, ovarian cancers, and melanoma[1][4][8]. Researchers focused on colorectal cancer because it has become a leading cause of cancer-related deaths among individuals under 50 and often resists current treatments[4][9][11].

The timeline

Previous research in March 2019 highlighted PPARD's role in promoting colorectal cancer progression[6]. Studies as recent as June 2024 explored PPARD inhibitors for therapeutic purposes[7]. This new discovery, published on October 14, 2026, presents a different strategy by leveraging the protein's potential within the immune system itself[2][4][5].

What changed and for whom

This research represents a shift in understanding PPARD's role, from solely being a promoter of disease in cancer cells to becoming a potent anti-cancer force when activated in immune cells[4][12]. This paradigm shift could eventually benefit patients with difficult-to-treat cancers for which current immunotherapies are ineffective[4][8]. Beyaz likened PPARD's dual nature to "the force" in Star Wars, capable of promoting disease or fighting it, depending on its activation[12]. The CSHL laboratory is also investigating whether enhancing immune cell metabolic activity using this principle could help treat endometriosis, a chronic inflammatory disease[4][8][12][13].

What we could not confirm

This method has not yet been tested in human patients. Its clinical effectiveness requires further assessment through future studies[4].